Shengxiang Ren

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4K citations

Medicine, Pathology, Bronchial Neoplasm +8

Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer

Fengying Wu, Jue Fan, Yayi He et al. · Nature Communications · 2021 · 759 citations · Full text

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 464 citations

Non-small-cell Lung Cancer, Medicine, Pathology +8

Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer

Sha Zhao, Shengxiang Ren, Tao Jiang et al. · Cancer Immunology Research · 2019 · 329 citations

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 293 citations

Camrelizumab Plus Carboplatin, Medicine, Advanced Squamous Nsclc +8